| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mutation | 21 | 2025 | 2456 | 1.840 |
Why?
|
| Biomarkers, Tumor | 12 | 2025 | 461 | 1.710 |
Why?
|
| Adenocarcinoma | 6 | 2024 | 323 | 1.710 |
Why?
|
| High-Throughput Nucleotide Sequencing | 11 | 2025 | 263 | 1.660 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2021 | 71 | 1.270 |
Why?
|
| DNA Mutational Analysis | 11 | 2025 | 188 | 0.850 |
Why?
|
| Pancreatic Cyst | 2 | 2019 | 24 | 0.800 |
Why?
|
| In Situ Hybridization, Fluorescence | 6 | 2016 | 152 | 0.770 |
Why?
|
| Immunohistochemistry | 17 | 2023 | 847 | 0.750 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2021 | 289 | 0.730 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2025 | 236 | 0.710 |
Why?
|
| Urothelium | 2 | 2020 | 22 | 0.690 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2021 | 28 | 0.680 |
Why?
|
| Proto-Oncogene Proteins B-raf | 6 | 2020 | 51 | 0.670 |
Why?
|
| Leukemia, Myeloid, Acute | 5 | 2025 | 167 | 0.650 |
Why?
|
| Pancreatic Neoplasms | 2 | 2019 | 331 | 0.630 |
Why?
|
| Appendiceal Neoplasms | 1 | 2018 | 8 | 0.620 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2018 | 30 | 0.610 |
Why?
|
| Thymosin | 4 | 2007 | 8 | 0.610 |
Why?
|
| Hemangiosarcoma | 2 | 2015 | 23 | 0.600 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2015 | 96 | 0.600 |
Why?
|
| Papillomavirus Infections | 4 | 2025 | 120 | 0.590 |
Why?
|
| Middle Aged | 33 | 2025 | 16314 | 0.560 |
Why?
|
| Myelodysplastic Syndromes | 4 | 2025 | 75 | 0.560 |
Why?
|
| Cytodiagnosis | 2 | 2016 | 44 | 0.550 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2021 | 68 | 0.540 |
Why?
|
| Pathology, Molecular | 1 | 2016 | 10 | 0.530 |
Why?
|
| Aged | 29 | 2025 | 13406 | 0.520 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2016 | 16 | 0.520 |
Why?
|
| Humans | 67 | 2025 | 59389 | 0.490 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2015 | 21 | 0.480 |
Why?
|
| MAP Kinase Signaling System | 1 | 2016 | 203 | 0.460 |
Why?
|
| Lung Diseases | 1 | 2016 | 170 | 0.460 |
Why?
|
| Prostatic Neoplasms | 4 | 2007 | 339 | 0.450 |
Why?
|
| Adult | 22 | 2025 | 15683 | 0.450 |
Why?
|
| Simplexvirus | 5 | 1995 | 25 | 0.450 |
Why?
|
| Aged, 80 and over | 17 | 2025 | 5119 | 0.450 |
Why?
|
| Barrett Esophagus | 2 | 2011 | 30 | 0.440 |
Why?
|
| Female | 35 | 2025 | 30724 | 0.430 |
Why?
|
| Human papillomavirus 16 | 2 | 2021 | 17 | 0.430 |
Why?
|
| Male | 37 | 2025 | 27747 | 0.420 |
Why?
|
| Anus Neoplasms | 2 | 2025 | 23 | 0.420 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2024 | 55 | 0.400 |
Why?
|
| Viral Proteins | 4 | 1995 | 253 | 0.390 |
Why?
|
| Endothelial Cells | 3 | 2022 | 173 | 0.380 |
Why?
|
| Human papillomavirus 18 | 1 | 2011 | 4 | 0.380 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2021 | 411 | 0.380 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2011 | 28 | 0.370 |
Why?
|
| Hemangioendothelioma, Epithelioid | 2 | 2021 | 7 | 0.370 |
Why?
|
| Stem Cell Transplantation | 2 | 2011 | 75 | 0.370 |
Why?
|
| Myofibroblasts | 1 | 2010 | 15 | 0.350 |
Why?
|
| Endothelium | 1 | 2010 | 18 | 0.350 |
Why?
|
| Urine | 2 | 2021 | 38 | 0.350 |
Why?
|
| Sweat Gland Neoplasms | 2 | 2024 | 20 | 0.350 |
Why?
|
| Neoplastic Stem Cells | 4 | 2019 | 196 | 0.340 |
Why?
|
| Neoplasm Staging | 6 | 2021 | 448 | 0.340 |
Why?
|
| Bone Marrow Cells | 1 | 2010 | 234 | 0.330 |
Why?
|
| Retinoblastoma Binding Proteins | 2 | 2019 | 6 | 0.310 |
Why?
|
| Receptor, ErbB-4 | 2 | 2019 | 9 | 0.310 |
Why?
|
| Adenoma, Oxyphilic | 2 | 2019 | 11 | 0.310 |
Why?
|
| Cyst Fluid | 2 | 2019 | 5 | 0.310 |
Why?
|
| Molecular Targeted Therapy | 3 | 2019 | 121 | 0.300 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2019 | 83 | 0.290 |
Why?
|
| Breast Neoplasms | 3 | 2018 | 1118 | 0.290 |
Why?
|
| Carcinoma | 2 | 2020 | 116 | 0.290 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2024 | 318 | 0.290 |
Why?
|
| Kidney Neoplasms | 2 | 2019 | 125 | 0.280 |
Why?
|
| Sensitivity and Specificity | 5 | 2017 | 1091 | 0.280 |
Why?
|
| Diagnosis, Differential | 6 | 2019 | 931 | 0.270 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2019 | 210 | 0.270 |
Why?
|
| Cell Fusion | 4 | 1995 | 37 | 0.270 |
Why?
|
| Prognosis | 5 | 2025 | 1597 | 0.270 |
Why?
|
| ras Proteins | 3 | 2016 | 77 | 0.260 |
Why?
|
| CD56 Antigen | 2 | 2021 | 15 | 0.260 |
Why?
|
| Repressor Proteins | 3 | 2024 | 331 | 0.250 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2019 | 179 | 0.250 |
Why?
|
| Skin Neoplasms | 2 | 2024 | 397 | 0.250 |
Why?
|
| MafG Transcription Factor | 2 | 2016 | 5 | 0.240 |
Why?
|
| Deubiquitinating Enzyme CYLD | 1 | 2025 | 4 | 0.240 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2025 | 8 | 0.240 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2021 | 193 | 0.240 |
Why?
|
| Histiocytic Sarcoma | 2 | 2016 | 4 | 0.230 |
Why?
|
| Neoplasm Grading | 3 | 2020 | 79 | 0.220 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 446 | 0.220 |
Why?
|
| Proctitis | 1 | 2023 | 6 | 0.220 |
Why?
|
| Nevus | 1 | 2024 | 18 | 0.220 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 3 | 2014 | 49 | 0.220 |
Why?
|
| Dioxygenases | 1 | 2024 | 25 | 0.220 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2020 | 170 | 0.220 |
Why?
|
| Viral Envelope Proteins | 3 | 1993 | 100 | 0.220 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2025 | 168 | 0.210 |
Why?
|
| Chlamydia Infections | 1 | 2023 | 76 | 0.210 |
Why?
|
| Survival Rate | 4 | 2020 | 801 | 0.210 |
Why?
|
| CpG Islands | 2 | 2014 | 211 | 0.210 |
Why?
|
| Cell Cycle Proteins | 1 | 2025 | 384 | 0.200 |
Why?
|
| Gene Silencing | 2 | 2016 | 378 | 0.200 |
Why?
|
| Cytogenetic Analysis | 2 | 2020 | 23 | 0.200 |
Why?
|
| beta Catenin | 2 | 2021 | 86 | 0.200 |
Why?
|
| Colorectal Neoplasms | 2 | 2016 | 263 | 0.190 |
Why?
|
| Lymphatic Vessels | 1 | 2022 | 31 | 0.190 |
Why?
|
| Polymerase Chain Reaction | 4 | 2016 | 495 | 0.190 |
Why?
|
| Uterine Neoplasms | 2 | 2020 | 29 | 0.190 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 1027 | 0.190 |
Why?
|
| Vascular Neoplasms | 1 | 2021 | 16 | 0.180 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2021 | 11 | 0.180 |
Why?
|
| Melanoma | 2 | 2016 | 318 | 0.180 |
Why?
|
| Anal Canal | 1 | 2021 | 34 | 0.180 |
Why?
|
| Endometrial Neoplasms | 2 | 2020 | 53 | 0.180 |
Why?
|
| Antibodies, Bispecific | 1 | 2021 | 29 | 0.180 |
Why?
|
| Urinary Bladder | 1 | 2021 | 38 | 0.180 |
Why?
|
| Urologic Neoplasms | 1 | 2020 | 15 | 0.170 |
Why?
|
| Hodgkin Disease | 2 | 2013 | 55 | 0.170 |
Why?
|
| Leukemia, Neutrophilic, Chronic | 1 | 2020 | 4 | 0.170 |
Why?
|
| Leukocytosis | 1 | 2020 | 11 | 0.170 |
Why?
|
| Adenosarcoma | 1 | 2020 | 4 | 0.170 |
Why?
|
| Lymphoma, B-Cell | 2 | 2013 | 59 | 0.170 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2020 | 6 | 0.170 |
Why?
|
| Ampulla of Vater | 1 | 2020 | 12 | 0.170 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2020 | 17 | 0.170 |
Why?
|
| DNA-Binding Proteins | 3 | 2024 | 1151 | 0.170 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2020 | 29 | 0.170 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2019 | 14 | 0.170 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2019 | 14 | 0.160 |
Why?
|
| Nuclear Proteins | 2 | 2014 | 750 | 0.160 |
Why?
|
| Oncogenes | 2 | 2018 | 66 | 0.160 |
Why?
|
| Thiazolidines | 1 | 2019 | 14 | 0.160 |
Why?
|
| Biphenyl Compounds | 1 | 2019 | 31 | 0.160 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 2338 | 0.160 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2020 | 205 | 0.160 |
Why?
|
| Animals | 18 | 2022 | 19650 | 0.160 |
Why?
|
| Pyrimidines | 2 | 2022 | 131 | 0.160 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 10 | 0.160 |
Why?
|
| Pancreas | 1 | 2019 | 146 | 0.160 |
Why?
|
| Fusion Proteins, bcr-abl | 2 | 2019 | 32 | 0.160 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2011 | 65 | 0.150 |
Why?
|
| Young Adult | 5 | 2025 | 4272 | 0.150 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 147 | 0.150 |
Why?
|
| Receptors, Somatomedin | 1 | 2018 | 10 | 0.150 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2016 | 191 | 0.150 |
Why?
|
| DNA Methylation | 3 | 2016 | 271 | 0.150 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2008 | 39 | 0.150 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 394 | 0.150 |
Why?
|
| Carcinoma, Lobular | 1 | 2018 | 23 | 0.150 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2018 | 55 | 0.140 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 266 | 0.140 |
Why?
|
| Lymph Nodes | 3 | 2018 | 215 | 0.140 |
Why?
|
| Lung Neoplasms | 2 | 2014 | 584 | 0.140 |
Why?
|
| Immunophenotyping | 5 | 2021 | 184 | 0.140 |
Why?
|
| Head and Neck Neoplasms | 2 | 2016 | 148 | 0.140 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2016 | 4 | 0.140 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2016 | 8 | 0.140 |
Why?
|
| Disease Progression | 5 | 2024 | 1119 | 0.140 |
Why?
|
| 5-Methylcytosine | 1 | 2016 | 20 | 0.130 |
Why?
|
| Molecular Sequence Data | 6 | 2014 | 1951 | 0.130 |
Why?
|
| Eyelid Neoplasms | 1 | 2016 | 9 | 0.130 |
Why?
|
| Lipase | 1 | 2017 | 48 | 0.130 |
Why?
|
| Gene Deletion | 1 | 2018 | 293 | 0.130 |
Why?
|
| Tetrasomy | 1 | 2016 | 3 | 0.130 |
Why?
|
| Laboratories | 1 | 2016 | 27 | 0.130 |
Why?
|
| Mucins | 1 | 2016 | 25 | 0.130 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2016 | 15 | 0.130 |
Why?
|
| Sarcoma | 1 | 2016 | 36 | 0.130 |
Why?
|
| Neoplasm Metastasis | 3 | 2020 | 186 | 0.130 |
Why?
|
| Epigenesis, Genetic | 2 | 2016 | 357 | 0.130 |
Why?
|
| Retrospective Studies | 4 | 2023 | 6071 | 0.130 |
Why?
|
| Liver | 1 | 2020 | 795 | 0.130 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2015 | 40 | 0.120 |
Why?
|
| Recombinant Proteins | 4 | 2005 | 689 | 0.120 |
Why?
|
| PAX5 Transcription Factor | 2 | 2012 | 12 | 0.120 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2015 | 27 | 0.120 |
Why?
|
| Biopsy | 1 | 2016 | 410 | 0.120 |
Why?
|
| Vero Cells | 5 | 1995 | 76 | 0.120 |
Why?
|
| Up-Regulation | 5 | 2016 | 365 | 0.120 |
Why?
|
| DNA | 1 | 2019 | 805 | 0.120 |
Why?
|
| Herpesvirus 1, Human | 1 | 1995 | 78 | 0.120 |
Why?
|
| Fixatives | 1 | 2014 | 17 | 0.120 |
Why?
|
| Fatal Outcome | 4 | 2020 | 116 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2013 | 402 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2007 | 300 | 0.110 |
Why?
|
| Prospective Studies | 2 | 2019 | 3067 | 0.110 |
Why?
|
| Glycoproteins | 2 | 1993 | 186 | 0.110 |
Why?
|
| Benzamides | 1 | 2014 | 63 | 0.110 |
Why?
|
| Mice | 7 | 2022 | 10294 | 0.110 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2014 | 10 | 0.110 |
Why?
|
| Vascular Diseases | 1 | 2015 | 75 | 0.110 |
Why?
|
| Genes, ras | 1 | 2014 | 27 | 0.110 |
Why?
|
| Piperazines | 1 | 2014 | 74 | 0.110 |
Why?
|
| Amino Acid Sequence | 5 | 2014 | 1553 | 0.110 |
Why?
|
| DNA Mismatch Repair | 1 | 2014 | 31 | 0.110 |
Why?
|
| Transplantation, Homologous | 2 | 2011 | 244 | 0.110 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2013 | 38 | 0.110 |
Why?
|
| Breast | 1 | 2015 | 174 | 0.110 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2013 | 7 | 0.110 |
Why?
|
| Mastocytosis, Systemic | 1 | 2013 | 5 | 0.110 |
Why?
|
| Clonal Evolution | 1 | 2013 | 3 | 0.100 |
Why?
|
| Mast Cells | 1 | 2013 | 41 | 0.100 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2012 | 25 | 0.100 |
Why?
|
| Lymphoma, Follicular | 1 | 2013 | 16 | 0.100 |
Why?
|
| Melanocytes | 1 | 2013 | 77 | 0.100 |
Why?
|
| Adolescent | 3 | 2023 | 5838 | 0.100 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2012 | 46 | 0.100 |
Why?
|
| Bone Marrow Transplantation | 1 | 2013 | 138 | 0.100 |
Why?
|
| Hematologic Neoplasms | 1 | 2013 | 44 | 0.100 |
Why?
|
| Carboplatin | 1 | 2012 | 40 | 0.100 |
Why?
|
| Boronic Acids | 1 | 2012 | 28 | 0.100 |
Why?
|
| src-Family Kinases | 1 | 2012 | 60 | 0.100 |
Why?
|
| Pyrazines | 1 | 2012 | 33 | 0.100 |
Why?
|
| Viral Fusion Proteins | 1 | 1992 | 54 | 0.100 |
Why?
|
| CCAAT-Enhancer-Binding Protein-beta | 1 | 2011 | 21 | 0.100 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2011 | 12 | 0.100 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2011 | 23 | 0.100 |
Why?
|
| Graft vs Host Disease | 1 | 2013 | 105 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 474 | 0.090 |
Why?
|
| Cervix Uteri | 1 | 2011 | 56 | 0.090 |
Why?
|
| Herpesvirus 4, Human | 1 | 2013 | 178 | 0.090 |
Why?
|
| Smoking | 1 | 2016 | 826 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 194 | 0.090 |
Why?
|
| Phenotype | 3 | 2025 | 1137 | 0.090 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 278 | 0.090 |
Why?
|
| Metaplasia | 1 | 2010 | 18 | 0.090 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 147 | 0.090 |
Why?
|
| Esophageal Neoplasms | 1 | 2011 | 79 | 0.090 |
Why?
|
| Stromal Cells | 1 | 2010 | 65 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 217 | 0.090 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 2 | 2024 | 28 | 0.090 |
Why?
|
| Transcription, Genetic | 1 | 2014 | 841 | 0.080 |
Why?
|
| Genes, Viral | 3 | 1995 | 55 | 0.080 |
Why?
|
| Cell Line, Tumor | 4 | 2016 | 1368 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2008 | 22 | 0.070 |
Why?
|
| Trisomy | 1 | 2008 | 19 | 0.070 |
Why?
|
| Epithelial Cells | 1 | 2010 | 391 | 0.070 |
Why?
|
| Disease Models, Animal | 2 | 2014 | 2053 | 0.070 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 2007 | 2 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2007 | 15 | 0.070 |
Why?
|
| Recurrence | 2 | 2008 | 602 | 0.070 |
Why?
|
| Imatinib Mesylate | 2 | 2019 | 33 | 0.070 |
Why?
|
| Chromosome Aberrations | 1 | 2007 | 62 | 0.070 |
Why?
|
| Collagen | 1 | 2007 | 115 | 0.070 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2007 | 118 | 0.070 |
Why?
|
| Liposarcoma | 1 | 2006 | 8 | 0.070 |
Why?
|
| Transcription Factors | 4 | 2021 | 1471 | 0.070 |
Why?
|
| Cell Membrane | 2 | 2001 | 486 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 2 | 2005 | 656 | 0.060 |
Why?
|
| United States | 2 | 2016 | 7426 | 0.060 |
Why?
|
| Consensus Sequence | 1 | 2005 | 29 | 0.060 |
Why?
|
| Neovascularization, Pathologic | 1 | 2006 | 137 | 0.060 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2005 | 30 | 0.060 |
Why?
|
| Prostate-Specific Antigen | 1 | 2005 | 66 | 0.060 |
Why?
|
| Prostatectomy | 1 | 2005 | 64 | 0.060 |
Why?
|
| Conserved Sequence | 1 | 2005 | 170 | 0.060 |
Why?
|
| MutL Protein Homolog 1 | 2 | 2014 | 24 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2019 | 883 | 0.060 |
Why?
|
| Protein Structure, Secondary | 1 | 2005 | 253 | 0.060 |
Why?
|
| Granulation Tissue | 1 | 2023 | 3 | 0.060 |
Why?
|
| Ulcer | 1 | 2023 | 14 | 0.060 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2024 | 82 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 1559 | 0.050 |
Why?
|
| Multiple Myeloma | 1 | 2008 | 325 | 0.050 |
Why?
|
| Gene Rearrangement | 2 | 2014 | 38 | 0.050 |
Why?
|
| Basement Membrane | 1 | 2022 | 25 | 0.050 |
Why?
|
| Adenoviridae | 2 | 1993 | 117 | 0.050 |
Why?
|
| Lymphatic System | 1 | 2022 | 18 | 0.050 |
Why?
|
| Pyridones | 1 | 2022 | 37 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2013 | 185 | 0.050 |
Why?
|
| Signal Transduction | 3 | 2021 | 2903 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2005 | 1051 | 0.050 |
Why?
|
| Glycosylation | 2 | 1992 | 129 | 0.050 |
Why?
|
| Blast Crisis | 1 | 2021 | 10 | 0.050 |
Why?
|
| Synaptophysin | 1 | 2021 | 6 | 0.050 |
Why?
|
| Genes, p53 | 1 | 2021 | 52 | 0.050 |
Why?
|
| Chromogranins | 1 | 2021 | 12 | 0.050 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2021 | 35 | 0.050 |
Why?
|
| Epidermal Growth Factor | 1 | 2001 | 48 | 0.050 |
Why?
|
| Cadherins | 1 | 2021 | 68 | 0.050 |
Why?
|
| Urinalysis | 1 | 2020 | 30 | 0.040 |
Why?
|
| Embryo Loss | 1 | 2020 | 10 | 0.040 |
Why?
|
| Adherens Junctions | 1 | 2020 | 8 | 0.040 |
Why?
|
| Gain of Function Mutation | 1 | 2020 | 12 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2014 | 356 | 0.040 |
Why?
|
| Heparin | 1 | 2001 | 111 | 0.040 |
Why?
|
| Diagnostic Errors | 1 | 2021 | 94 | 0.040 |
Why?
|
| Trans-Activators | 2 | 2012 | 300 | 0.040 |
Why?
|
| Microscopy | 1 | 2020 | 90 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2021 | 343 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2001 | 270 | 0.040 |
Why?
|
| Prevalence | 1 | 2023 | 1253 | 0.040 |
Why?
|
| Mass Screening | 1 | 2005 | 648 | 0.040 |
Why?
|
| Cell Communication | 1 | 2020 | 124 | 0.040 |
Why?
|
| bcl-Associated Death Protein | 1 | 2019 | 10 | 0.040 |
Why?
|
| Leukemia, Experimental | 1 | 2019 | 19 | 0.040 |
Why?
|
| STAT Transcription Factors | 1 | 2019 | 17 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2019 | 82 | 0.040 |
Why?
|
| Protein Isoforms | 3 | 2007 | 192 | 0.040 |
Why?
|
| Actins | 1 | 2000 | 259 | 0.040 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2018 | 29 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2012 | 197 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2000 | 357 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 1206 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2018 | 70 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 248 | 0.030 |
Why?
|
| Amylases | 1 | 2017 | 11 | 0.030 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2017 | 32 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2018 | 172 | 0.030 |
Why?
|
| Jaw | 1 | 2016 | 4 | 0.030 |
Why?
|
| Merkel cell polyomavirus | 1 | 2016 | 5 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 43 | 0.030 |
Why?
|
| History, 17th Century | 1 | 2016 | 5 | 0.030 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2016 | 38 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2001 | 697 | 0.030 |
Why?
|
| Brain Neoplasms | 2 | 2011 | 305 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 805 | 0.030 |
Why?
|
| Giant Cells | 1 | 1995 | 15 | 0.030 |
Why?
|
| Restriction Mapping | 1 | 1995 | 51 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2016 | 223 | 0.030 |
Why?
|
| Hexosaminidases | 1 | 1995 | 6 | 0.030 |
Why?
|
| Open Reading Frames | 1 | 1995 | 80 | 0.030 |
Why?
|
| Nuclear Envelope | 1 | 1995 | 48 | 0.030 |
Why?
|
| Oligosaccharides | 1 | 1995 | 58 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 1995 | 247 | 0.030 |
Why?
|
| raf Kinases | 1 | 2014 | 4 | 0.030 |
Why?
|
| Genome, Viral | 1 | 1995 | 120 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 1995 | 381 | 0.030 |
Why?
|
| Plasmids | 1 | 1995 | 279 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2014 | 21 | 0.030 |
Why?
|
| Alcohols | 1 | 2014 | 12 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2014 | 24 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2014 | 32 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2014 | 51 | 0.030 |
Why?
|
| Macrophages | 1 | 2020 | 1015 | 0.030 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2014 | 39 | 0.030 |
Why?
|
| Endoplasmic Reticulum | 1 | 1995 | 168 | 0.030 |
Why?
|
| Papanicolaou Test | 1 | 2014 | 42 | 0.030 |
Why?
|
| Child | 1 | 2023 | 4189 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2014 | 75 | 0.030 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2014 | 34 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2014 | 70 | 0.030 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1995 | 243 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor Proteins | 1 | 2014 | 16 | 0.030 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2014 | 17 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 2014 | 98 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 194 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2014 | 112 | 0.030 |
Why?
|
| Viral Plaque Assay | 1 | 1993 | 16 | 0.030 |
Why?
|
| Antibodies, Viral | 2 | 1993 | 297 | 0.030 |
Why?
|
| Fibroblasts | 1 | 1995 | 377 | 0.030 |
Why?
|
| Abnormal Karyotype | 1 | 2013 | 2 | 0.030 |
Why?
|
| Time Factors | 2 | 2016 | 3615 | 0.030 |
Why?
|
| Viral Structural Proteins | 1 | 1993 | 17 | 0.030 |
Why?
|
| Anemia, Hemolytic | 1 | 2013 | 12 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2014 | 554 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2013 | 31 | 0.030 |
Why?
|
| Clone Cells | 1 | 2013 | 106 | 0.030 |
Why?
|
| Tandem Repeat Sequences | 1 | 2012 | 26 | 0.030 |
Why?
|
| Gene Duplication | 1 | 2012 | 31 | 0.030 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2012 | 25 | 0.030 |
Why?
|
| Cytarabine | 1 | 2012 | 32 | 0.030 |
Why?
|
| Base Sequence | 1 | 1995 | 1302 | 0.030 |
Why?
|
| Cell-Free System | 1 | 1992 | 31 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2013 | 71 | 0.030 |
Why?
|
| Genes, abl | 1 | 2012 | 9 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2012 | 16 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2014 | 868 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2012 | 29 | 0.020 |
Why?
|
| K562 Cells | 1 | 2012 | 57 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2014 | 587 | 0.020 |
Why?
|
| Precipitin Tests | 1 | 1992 | 76 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 228 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 1993 | 2092 | 0.020 |
Why?
|
| Bortezomib | 1 | 2012 | 56 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2012 | 57 | 0.020 |
Why?
|
| Axilla | 1 | 2011 | 15 | 0.020 |
Why?
|
| Groin | 1 | 2011 | 14 | 0.020 |
Why?
|
| Pelvic Neoplasms | 1 | 2011 | 10 | 0.020 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2011 | 15 | 0.020 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2013 | 89 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 354 | 0.020 |
Why?
|
| CDX2 Transcription Factor | 1 | 2011 | 3 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2011 | 8 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2013 | 259 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 1995 | 608 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2011 | 38 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 650 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2011 | 119 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 76 | 0.020 |
Why?
|
| Biomarkers | 1 | 2017 | 1307 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2013 | 259 | 0.020 |
Why?
|
| Bile Acids and Salts | 1 | 2011 | 20 | 0.020 |
Why?
|
| Antigens, Viral | 1 | 1992 | 130 | 0.020 |
Why?
|
| Hysterectomy | 1 | 2011 | 65 | 0.020 |
Why?
|
| Karyotyping | 1 | 2011 | 44 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 1992 | 192 | 0.020 |
Why?
|
| Biological Transport | 1 | 1992 | 288 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 451 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2012 | 276 | 0.020 |
Why?
|
| Blotting, Western | 1 | 1992 | 583 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 306 | 0.020 |
Why?
|
| Palliative Care | 1 | 2013 | 214 | 0.020 |
Why?
|
| RNA Interference | 1 | 2014 | 590 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2014 | 941 | 0.020 |
Why?
|
| Rats | 2 | 2007 | 1910 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 1992 | 297 | 0.020 |
Why?
|
| Pneumonia | 1 | 2013 | 281 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 2001 | 450 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2011 | 254 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2012 | 5281 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2012 | 328 | 0.020 |
Why?
|
| DNA Damage | 1 | 2011 | 279 | 0.020 |
Why?
|
| Protein Conformation | 1 | 1992 | 763 | 0.020 |
Why?
|
| Sepsis | 1 | 2013 | 274 | 0.020 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2008 | 5 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2001 | 490 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 1504 | 0.020 |
Why?
|
| Transfection | 2 | 2001 | 675 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 858 | 0.020 |
Why?
|
| Binding Sites | 2 | 2001 | 881 | 0.020 |
Why?
|
| Cell Line | 1 | 1992 | 1983 | 0.020 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2007 | 9 | 0.020 |
Why?
|
| Parvovirus B19, Human | 1 | 2007 | 5 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 1993 | 808 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2012 | 1997 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 628 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2007 | 288 | 0.020 |
Why?
|
| Antibodies | 1 | 2007 | 179 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2006 | 15 | 0.020 |
Why?
|
| Protein Binding | 2 | 2001 | 1555 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 3231 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2006 | 513 | 0.010 |
Why?
|
| HIV Infections | 1 | 2011 | 913 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2007 | 1466 | 0.010 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2001 | 12 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 2001 | 33 | 0.010 |
Why?
|
| Etoposide | 1 | 2001 | 33 | 0.010 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2001 | 65 | 0.010 |
Why?
|
| Ubiquitins | 1 | 2001 | 41 | 0.010 |
Why?
|
| COS Cells | 1 | 2001 | 174 | 0.010 |
Why?
|
| CHO Cells | 1 | 2001 | 189 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2001 | 206 | 0.010 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2001 | 78 | 0.010 |
Why?
|
| Cricetinae | 1 | 2001 | 366 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2001 | 226 | 0.010 |
Why?
|
| Cell Division | 1 | 2001 | 443 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2000 | 248 | 0.010 |
Why?
|
| Cell Survival | 1 | 2001 | 559 | 0.010 |
Why?
|
| Cell Movement | 1 | 2000 | 428 | 0.010 |
Why?
|
| Apoptosis | 1 | 2001 | 1033 | 0.010 |
Why?
|
| Genetic Complementation Test | 1 | 1993 | 62 | 0.010 |
Why?
|
| Adsorption | 1 | 1993 | 82 | 0.010 |
Why?
|
| Mutagenesis, Insertional | 1 | 1993 | 89 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1993 | 472 | 0.010 |
Why?
|
| Endocytosis | 1 | 1993 | 149 | 0.010 |
Why?
|
| Virus Replication | 1 | 1993 | 305 | 0.010 |
Why?
|